文献速递炎症性肠病

炎症性肠病中的纤维化:从发病机制到治疗靶点

Fibrosis in IBD: from pathogenesis to therapeutic targets.
PubMed 文献 · Gut · 2024-04-05

本文综述炎症性肠病(IBD)中肠纤维化的发病机制、狭窄测量工具及临床试验终点开发现状。纤维化由免疫与非免疫细胞、可溶性介质及肠腔内容物暴露等多因素复杂过程引起,目前尚无抗纤维化治疗;共识定义与狭窄形态测量已有进展,但确定狭窄内纤维化程度的方法仍缺乏。

要点

  • IBD纤维化导致克罗恩病(CD)狭窄形成与梗阻,以及溃疡性结肠炎(UC)肠壁僵硬引发症状,属最大未满足需求之一。
  • 纤维化由免疫与非免疫细胞、可溶性介质及微生物和环境因素等多因素复杂过程引起。
  • 目前尚无抗纤维化治疗;共识定义与狭窄形态测量有进展,但确定狭窄内纤维化程度的方法仍缺乏。

核心结论

  • 在更好理解纤维化发病机制方面已取得显著进展,但需要额外研究和临床前开发来定义特定治疗靶点。

研究设计与样本

  • 本综述呈现和讨论的数据来源于过去和近期文献以及作者自己的研究和经验。

主要发现

  • 纤维化由涉及免疫与非免疫细胞、其可溶性介质以及暴露于肠腔内容物(如微生物群和环境因素)的多因素复杂过程引起。
  • 在创建共识定义和测量以量化临床实践和试验中的狭窄形态方面已取得一些进展,但确定狭窄内纤维化程度的方法仍然缺乏。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intestinal fibrosis resulting in stricture formation and obstruction in Crohn's disease (CD) and increased wall stiffness leading to symptoms in ulcerative colitis (UC) is among the largest unmet needs in inflammatory bowel disease (IBD). Fibrosis is caused by a multifactorial and complex process involving immune and non-immune cells, their soluble mediators and exposure to luminal contents, such as microbiota and environmental factors. To date, no antifibrotic therapy is available. Some progress has been made in creating consensus definitions and measurements to quantify stricture morphology for clinical practice and trials, but approaches to determine the degree of fibrosis within a stricture are still lacking. OBJECTIVE: We herein describe the current state of stricture pathogenesis, measuring tools and clinical trial endpoints development. DESIGN: Data presented and discussed in this review derive from the past and recent literature and the authors' own research and experience. RESULTS AND CONCLUSIONS: Significant progress has been made in better understanding the pathogenesis of fibrosis, but additional studies and preclinical developments are needed to define specific therapeutic targets.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Rieder F, Mukherjee PK, Massey WJ, et al. Fibrosis in IBD: from pathogenesis to therapeutic targets. Gut. 2024. PMID: 38233198. doi:10.1136/gutjnl-2023-329963

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。